Another study showed that the CB1 agonist delta9-tetrahydrocannabinol was able to control esophageal motility and reduce the transient LES relaxations associated with GERD onset, although this effect is likely to be mediated by the central nervous system [35]. This evidence concerns the gene CNR1 and gastroesophageal reflux disease.